title: A randomised controlled trial on melatonin and rosiglitazone for prevention of adhesion formation in a rat uterine horn model.
abstract: OBJECTIVE
  To investigate the effectiveness of melatonin and rosiglitazone in reducing postoperative adhesion formation in a rat uterine horn model.
  
  
  METHODS
  Thirty non-pregnant female Wistar albino rats, weighing 180-220 g, were used as a model for postoperative adhesion formation. The rats were randomised into three groups after seven standard lesions were inflicted in a 2-cm segment of each uterine horn and lower abdominal sidewall using bipolar cauterisation. The rats were treated with 10 mg/kg, intraperitoneal melatonin, and 1 mg/kg per day peroral rosiglitazone. No medication was given to the control group. As much as 20 uterine horns of 10 rats were evaluated in each group. Extent, severity, and degree of the adhesions to the uterine horns and, inflammation and fibrosis scores (histopathologically) were evaluated after 2 weeks of the treatment.
  
  
  RESULTS
  There was no mortality in the groups and all of the rats recovered without incident after operation. Rosiglitazone group had lower adhesion scores [median (min-max ranges)] regarding extent, severity, and degree of the adhesions [0 (0-3), 0 (0-3) and 0 (0-3), respectively], which were significantly different (P < 0.001, P < 0.05 and P < 0.01, respectively) from those of the controls [1 (0-3), 2 (0-2) and 2 (0-3), respectively]; however, there were no statistically significant differences between rosiglitazone versus melatonin groups [1 (0-4), 2 (0-3) and 1 (0-3), respectively] and melatonin versus control groups. Moreover, no significant differences were determined between groups regarding histopathologic findings.
  
  
  CONCLUSIONS
  Rosiglitazone, but not melatonin, is effective in prevention of adhesion formation in a rat uterine horn model.
authors.affiliation: Department of Obstetrics and Gynecology, Zekai Tahir Burak Women's Health Education and Research Hospital, Ankara, Turkey.
authors.forename: Orhan
authors.initials: O
authors.lastname: Aksakal
authors.forename: Bulent
authors.initials: B
authors.lastname: Yilmaz
authors.forename: Tayfun
authors.initials: T
authors.lastname: Gungor
authors.forename: Levent
authors.initials: L
authors.lastname: Sirvan
authors.forename: Necdet
authors.initials: N
authors.lastname: Sut
authors.forename: Ismet
authors.initials: I
authors.lastname: Inan
authors.forename: Senol
authors.initials: S
authors.lastname: Kalyoncu
authors.forename: Leyla
authors.initials: L
authors.lastname: Mollamahmutoglu
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage*; D004195:Disease Models, Animal; D005260:Female; D007274:Injections, Intraperitoneal; D008550:Melatonin / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000473:pathology / Q000517:prevention & control*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage*; D000267:Tissue Adhesions / Q000517:prevention & control*; D014591:Uterine Diseases / Q000473:pathology / Q000517:prevention & control*; D014599:Uterus / Q000601:surgery*
chemical_list: D000975:Antioxidants; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008550:Melatonin